Trending
Meet Vpply: ‘TikTok for jobs’
Australian-owned job board, Vpply, is connecting companies and job seekers through quick and engaging video, allowing candidates to showcase their personality without the need of traditional resumes.
Moving to Venture Investing 3.0
The next ten years are going to be the most disruptive – and potentially the most profitable – in the history of venture capital. Learn what technologies and techniques you need to adopt in order to become a successful, next-generation private market investor from this keynote presentation by Hatcher+ Managing Partner John Sharp. Looking for […]
SYNCOGATE making ground-breaking headway into global digital education
Syncogate has formed strategic partnerships in Australia, China, Indonesia and Malaysia and has just signed a ground-breaking agreement with ALEF Education.
Video Job Board Vpply Generates 217% growth in 5 months and Introduces AI Tools
Vpply was launched in 2020 with the aim to cut the recruitment cycle for employers from weeks to days by eliminating mass CVs and viewing an immediate shortlist for their listed jobs via video
Income2Wealth announces $2,681,942 distributions paid in July 2022
Income2Wealth is focused on providing a wide variety of investment pathways aimed at helping people achieve their short and long term investment goals.
Transcount partners with Ondato and United Arab Supply Chain
Transcount has a partnership with Ondato, a Lithuanian-based EU-compliant eSignature provider in 170 countries
ALTECH – Halloysite Discovered at Kerrigan Kaolin Deposit
Altech Chemicals Limited (Altech/the Company) (ASX: ATC) (FRA: A3Y) is pleased to announce the
discovery of halloysite at its Kerrigan kaolin deposit in Western Australia. The halloysite was observed
EG Private Wealth sold a $26M industrial site, secured strong return for investors in excess of 27% p.a.
EG sold an industrial site at 22 Narabang Way, Belrose for $26M, realising returns for its Private Wealth investors in excess of 27% p.a. over a 2.5-year hold period.
Kazia completes recruitment of patients for phase I clinical study of Cantrixil in ovarian cancer
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has completed recruitment of patients into Part B of its phase
Backed By Leading Investment Groups and Family Offices
